Bevacizumab is a human monoclonal antibody against VEGF. Many adverse reactions about bevacizumab are identified including venous and arterial thromboembolism, nausea, fatigue, alopecia, proteinuria, gastrointestinal system (GIS) perforation, exfoliative dermatitis, and peripheral edema and thrombocytopenia. In this paper, we report a case of bevacizumab-induced dose-dependent, toxicity-mediated drug-induced thrombotic microangiopathy.
George JN and Nester C. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371(19): 1847–8.
5.
SchwartzJPadmanabhanAAquiN, et al.Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: the seventh special issue. J Clin Apher2016; 31: 149–149.
6.
Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 2017; 15(2): 312–322.
7.
RiedlMFakhouriFLe QuintrecM, et al.Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost2014; 40: 444–444.
